Locally Advanced Cervical Cancer clinical trials

Explore recruiting locally advanced cervical cancer clinical trials.

Recruiting locally advanced cervical cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Locally Advanced Cervical Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Induction chemotherapy followed by standard concurrent chemoradiotherapy in cervical cancer with para-aortic lymph node involvement: A phase III, multicenter, parallel-group randomized, controlled trial - ONCOCOL-01

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Randomized Phase II Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab in Locally Advanced Cervical Cancer (AtezoLACC)

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase II single arm open label study of Pembrolizumab and Lenvatinib in patients with high risk locally advanced cervix cancer: an EMBRACE high risk study initiative

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase III, Randomized, Double blind, Placebo controlled, Multi centre, Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum based, Concurrent Chemoradiation Therapy (eVOLVE Cervical)

Poland, Italy, Norway, Denmark, Germany, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer (KEYNOTE-A18 / ENGOT-cx11/GOG-3047)

Germany, Norway, Ireland, Belgium, Spain, France +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A randomized, open label, phase II trial of Anti-PD1, dostarlimab (TSR-042), as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemo-radiation

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Locally Advanced Cervical Cancer trials by city

Locally Advanced Cervical Cancer in Toronto Locally Advanced Cervical Cancer in Vancouver Locally Advanced Cervical Cancer in Montreal Locally Advanced Cervical Cancer in Calgary Locally Advanced Cervical Cancer in Edmonton Locally Advanced Cervical Cancer in Ottawa Locally Advanced Cervical Cancer in Winnipeg Locally Advanced Cervical Cancer in Quebec City Locally Advanced Cervical Cancer in Hamilton Locally Advanced Cervical Cancer in Kitchener Locally Advanced Cervical Cancer in London Locally Advanced Cervical Cancer in Halifax Locally Advanced Cervical Cancer in New York Locally Advanced Cervical Cancer in Los Angeles Locally Advanced Cervical Cancer in Chicago Locally Advanced Cervical Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease